Presenting at the Hardman Private Investor Forum

RNS Number : 2489E

Avacta Group PLC

05 May 2017

 

5 May 2017

Avacta Group plc

("Avacta" or "the Group" or "the Company")

Avacta to Present at the Hardman Private Investor Forum

Avacta Group plc (AIM: AVCT), the developer of Affimer^® biotherapeutics and research reagents, is pleased to announce that its Chief Executive, Alastair Smith, will be presenting at the Hardman Private Investor Forum on Tuesday 9^th May in London at the University of Liverpool, 33 Finsbury Square, EC2A 1AG.

The evening event, which begins with registration at 17:30, provides an opportunity for investors to hear about the Company's Affimer® technology, its development plans and to discuss these with Alastair, Philippe Cotrel, the Company's Chief Commercial Officer, and with Dr Trevor Nicholls, Chairman of the Board.

ENDS

NOTES

For further information from Avacta Group plc, please contact:

Avacta Group plc Alastair Smith, Chief Executive Officer Tony Gardiner, Chief Financial Officer	Tel:  [phone] www.avacta.com
finnCap Ltd Geoff Nash / Giles Rolls - Nominated Adviser Tim Redfern / Alice Lane - Corporate Broking WG Partners Nigel Birks / Nigel Barnes David Wilson / Claes Spang	Tel:  [phone] www.finncap.com Tel:  [phone] Tel:  [phone] www.wgpartners.co.uk
Zyme Communications (Trade and Regional Media) Katie Odgaard FTI Consulting (Financial Media and IR) Simon Conway / Natalie Garland-Collins	Tel: [phone] [e-mail]  Tel: [phone] [e-mail]

About Avacta Group plc (www.avacta.com)

Avacta's principal focus is on its proprietary Affimer^® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

Affimer technology has been designed to address many of the negative performance issues of antibodies, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of targets.

Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.

 

END

 

 

NRALLFEEEIISIID